Olga Kalashnikova

Dr. Olga Kalashnikova


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2023 in Children
Verified
Journal Article
Open access
PDF file
IAIlia Avrusin
Ilia Avrusin
NANatalia N. Abramova
Natalia N. Abramova
KBKonstantin E. Belozerov
Konstantin E. Belozerov
GKGleb V. Kondratiev
Gleb V. Kondratiev
LBLiudmila V. Bregel
Liudmila V. Bregel
Mikhail KostikMikhail Kostik
Mikhail Kostik
Multisystem inflammatory syndrome associated with COVID-19 in children (MIS-C) is a life-threatening condition that often requires intensive care unit (ICU) admission. The aim of this study was to determine risk factors for severe/life-threatening course of MIS-C. The study included 166 patients (99 boys, 67 girls) aged 4 months–17 years (median 8.2 years). The criterion of severity was the fact of ICU admission. To conduct a comparative analysis, MIS-C patients were divided into two groups: patients hospitalized in the ICU (n = 84, 50.6%) and those who did not need ICU admission (n = 82, 49.4%). Patients with a more severe course of MIS-C were significantly older. They had a higher frequency of signs such as rash, swelling, hepatomegaly, splenomegaly, and neurological and respiratory symptoms. Hypotension/shock and myocardial involvement were much more common in patients with severe MIS-C. These patients had a more significant increase in CRP, creatinine, troponin, and D-dimer levels. Additionally, the presence of macrophage activation syndrome was higher in patients admitted to the ICU. Conclusion: Nineteen predictors of severe course of MIS-C were found, out of which hepatomegaly, splenomegaly, D-dimer > 2568 ng/mL, troponin > 10 pg/mL were mainly associated with the probability of being classified as early predictors of severe MIS-C requiring ICU admission.

23 January 2015 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
Mikhail KostikMikhail Kostik
Mikhail Kostik
MDMargarita F Dubko
Margarita F Dubko
VMVera V Masalova
Vera V Masalova
LSLudmila S Snegireva
Ludmila S Snegireva
TKTatyana L Kornishina
Tatyana L Kornishina
VCVyacheslav Chasnyk
Vyacheslav Chasnyk
Systemic juvenile idiopathic arthritis (SoJIA) is the most striking form of juvenile idiopathic arthritis. The aim of our study was to evaluate the clinical responses and outcomes of children with SoJIA to IL-6 blockade using two different tocilizumab (TCZ) treatment protocols designed for milder and more severe SoJIA patient groups, and evaluate the possibility of achieving biologic-free remission.

27 January 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
IAIlia Avrusin
Ilia Avrusin
NANatalia N. Abramova
Natalia N. Abramova
KBKonstantin E. Belozerov
Konstantin E. Belozerov
LBLiudmila V. Bregel
Liudmila V. Bregel
OEOlesya S. Efremova
Olesya S. Efremova
Mikhail KostikMikhail Kostik
Mikhail Kostik
Hemophagocytic syndrome is a key point in the pathogenesis of severe forms of multisystem inflammatory syndrome associated with COVID-19 in children (MIS-C). The factors associated with hemophagocytosis in patients with MIS-C were assessed in the present study of 94 boys and 64 girls ranging in age from 4 months to 17 years, each of whose HScore was calculated. In accordance with a previous analysis, patients with HScore ≤ 91 (n = 79) and HScore > 91 (n = 79) were compared. Patients with HScore > 91 had a higher frequency of symptoms such as cervical lymphadenopathy, dry cracked lips, bright mucous, erythema/swelling of hands and feet, peeling of fingers, edematous syndrome, hepatomegaly, splenomegaly, and hypotension/shock. They also had a higher erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and D-dimer levels, and a tendency to anemia, thrombocytopenia, and hypofibrinogenemia. They more often needed acetylsalicylic acid and biological treatment and were admitted to ICU in 70.9% of cases. Conclusion: The following signs of severe MIS-C were associated with HScore > 91: myocardial involvement, pericarditis, hypotension/shock, and ICU admission.

13 March 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
KBKonstantin E. Belozerov
Konstantin E. Belozerov
IAIlia Avrusin
Ilia Avrusin
LALyubov I. Andaryanova
Lyubov I. Andaryanova
AGAnna M. Guseva
Anna M. Guseva
ZSZaira S. Shogenova
Zaira S. Shogenova
Mikhail KostikMikhail Kostik
Mikhail Kostik
Background: Several cases of skin and central nervous system vasculopathy associated with COVID-19 in children have been published, but the information is rather limited. Our study aimed to describe these cases of vasculitis associated with COVID-19 in children. Methods: In the retrospective-prospective case series study we included information regarding four children with COVID-19-associated vasculitis. In every case, we had a morphological description and the etiology was confirmed via real-time polymerase chain reaction during a tissue biopsy. Results: The most involved systems were skin (4/4), respiratory (3/4), cardiovascular (2/4), nervous (1/4), eye (1/4), kidney (1/4), and inner year (1/4). All patients had increased inflammatory markers and thrombotic parameters (D-dimer). No patient met the criteria for multisystem inflammatory syndrome in children. Two patients met polyarteritis nodosa criteria, one met Henoch–Schonlein purpura criteria, and one met unclassified vasculitis criteria. All patients were treated with systemic glucocorticosteroids (two-pulse therapy). Non-biologic DMARDs were prescribed in all cases; 1/4 patients (25%) was treated with intravenous immunoglobuline, and 3/4 (75%) were treated with biologics (etanercept, tocilizumab, and adalimumab). Conclusions: Vasculitis associated with COVID-19 could be a life-threatening condition; SARS-CoV-2 might be a new trigger or etiological agent for vasculitis and other immune-mediated diseases. Further research and collection of similar cases are required.

2 March 2022 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
IAIlia Avrusin
Ilia Avrusin
RRRinat Raupov
Rinat Raupov
NGN. T. Garipova
N. T. Garipova
MGM. M. Gharabaghtsyan
M. M. Gharabaghtsyan
SKS. V. Khrypov
S. V. Khrypov
Mikhail KostikMikhail Kostik
Mikhail Kostik
Systemic corticosteroids are continued to be administered in juvenile idiopathic arthritis (JIA) patients, especially in systemic JIA (sJIA), despite the ability of biologic therapy. One of the complications of long-term CS treatment is delayed hip arthritis development with risk of secondary hip osteoarthritis formation and total hip arthroplasty (THA).We compared different types of hip joint lesions in JIA, especially, secondary hip osteoarthritis development and THA rates in systemic and non-systemic JIA, and evaluate systemic corticosteroids contribution to those complications.The study included 753 JIA patients. They were divided into 2 groups: patients with sJIA and non-systemic JIA (nsJIA). Clinical and demographic characteristics, CS treatment regimens were compared.Results. Hip arthritis was found equally often in both groups, but both secondary hip osteoarthritis (19% vs 5,3%) and THA (8.6% vs 1.6%) prevailed in the sJIA. Patients with sJIA had delayed hip involvement (57.9% vs 30.6%; p=0.019), earlier secondary hip osteoarthritis development (4.5 vs 5.1 years after the JIA onset) with younger age of secondary hip osteoarthritis achievement (13.7 vs 15.2 years; р=0.045), they also had higher inflammatory activity, greater systemic corticosteroids administration (94.8% vs 56.1%; р=0.0000001) and higher cumulative systemic corticosteroids dose (3085 mg vs 2000 mg; p=0,005). More than half patients (56.1%) with nsJIA had systemic corticosteroids treatment and impaired calcium-phosphorus metabolism.Conclusion. Systemic corticosteroid treatment and delayed hip involvement are independent predictors of secondary hip osteoarthritis in all JIA categories. Calcium and phosphate metabolism disturbances are additional predictor for secondary hip osteoarthritis in non-systemic JIA categories

1 January 2016 in Current Pediatrics
Verified
Journal Article
Open access
PDF file
Mikhail KostikMikhail Kostik
Mikhail Kostik
EKE. M. Kuchinskaya
E. M. Kuchinskaya
FAF. N. Abduragimova
F. N. Abduragimova
OGO. P. Gurina
O. P. Gurina
OKOlga Kalashnikova
Olga Kalashnikova
VCVyacheslav Chasnyk
Vyacheslav Chasnyk
Опыт применения ритуксимаба у детей с системной красной волчанкой: ретроспективное исследование серии случаев